Rhea-AI Summary
ImmunoGen, a leader in antibody-drug conjugates for cancer treatment, announced the grant of non-qualified stock options for 8,400 shares to a new employee on September 30, 2020, under its Inducement Equity Incentive Plan. This award, made in compliance with Nasdaq Listing Rule 5635(c)(4), has an exercise price of $3.60 per share, matching the company's closing stock price on that date. The options will vest over four years, incentivizing long-term employment. ImmunoGen is committed to developing targeted therapies to improve cancer patient outcomes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.59%
Tags